Compare PZZA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZZA | COLL |
|---|---|---|
| Founded | 1984 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1993 | 2015 |
| Metric | PZZA | COLL |
|---|---|---|
| Price | $42.03 | $46.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $49.44 | $45.40 |
| AVG Volume (30 Days) | ★ 2.5M | 624.2K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.14 | ★ 1.63 |
| Revenue | ★ $2,086,399,000.00 | $757,067,000.00 |
| Revenue This Year | $4.45 | $21.41 |
| Revenue Next Year | $0.93 | $3.28 |
| P/E Ratio | $36.96 | ★ $28.72 |
| Revenue Growth | N/A | ★ 26.34 |
| 52 Week Low | $30.16 | $23.23 |
| 52 Week High | $55.74 | $48.18 |
| Indicator | PZZA | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 73.19 |
| Support Level | $38.40 | $45.33 |
| Resistance Level | $42.68 | $46.48 |
| Average True Range (ATR) | 2.43 | 1.63 |
| MACD | 0.23 | -0.01 |
| Stochastic Oscillator | 34.18 | 73.95 |
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.